Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam

Arcutis Biotherapeutics (ARQT) announced the U.S. Food and Drug Administration has approved the supplemental New Drug Application for Zoryve topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. Zoryve foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis. “With approval for cream and now the foam formulations, individuals and clinicians can choose their preferred administration of Zoryve with powerful, long-term relief of plaques and itch anywhere on the body, including hair-bearing areas, with no limitation on duration of use,” said Frank Watanabe, president and Chief Executive Officer of Arcutis. “Leveraging our deep medical dermatology expertise, we intentionally formulated Zoryve to meet the needs of individuals with psoriasis, including hard-to-treat areas from head to toe. This is the fifth approval for Zoryve in less than three years and furthers our mission to deliver new treatment options that address the urgent needs of individuals suffering from chronic inflammatory skin diseases.”